← Eichor
Condition: Hiv Status Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Hiv Status

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Zn Supplementation in HIV Immunological Non Responders
NA · 1 location(s) · Parc de Salut Mar · NCT06612554
The DC Cohort Longitudinal HIV Status Neutral Study
Phase N/A · 14 location(s) · George Washington University · NCT01206920
J-RISE: Relevant Implementation Strategies to Eliminate the Social and Structural Barriers to HIV Services Among Justice
NA · 1 location(s) · University of Chicago · NCT06477588
High vs. Standard Dose Rifampicin for Effusive Tuberculous Pericarditis
Phase 2 · 2 location(s) · University of Cape Town · NCT04521803
Healer-initiated HIV Counseling and Testing Versus Standard of Care in Rural South Africa
NA · 1 location(s) · Vanderbilt University Medical Center · NCT06483854
Behavioral Activation and Risk Reduction for Stimulant Use Among Sexually Active Adolescents and Young Adults
NA · 2 location(s) · Westat · NCT06444360
Case Management Dyad
NA · 1 location(s) · University of Chicago · NCT06162897
Augmented Renal Clearance in Neurocritical Care
Phase N/A · 3 location(s) · University of Alberta · NCT07410624
Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis
NA · 1 location(s) · Albert Einstein College of Medicine · NCT06590428
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.